# Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

> **NCT07155200** · PHASE1,PHASE2 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 42 (estimated)

## Conditions studied

- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer

## Interventions

- **DRUG:** Cirtuvivint
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT07155200
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2028-07-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07155200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07155200, "Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07155200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*